Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Nasopharyngeal carcinoma, drawn from the whole corpus: 21 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Radiation late effects in a disease cured young.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Western access to PD-1 inhibitors studied in Asia; regulatory lag.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
EBV-targeted therapy (vaccines, EBV-specific T cells) still investigational.
Distant metastasis is the main way treatment fails after chemoradiation; plasma EBV DNA now identifies who needs more.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 21 changes by month →When this page itself was last checked or edited.
Recurrent or metastatic non-keratinising NPC with cisplatin-gemcitabine; monotherapy after platinum and ≥1 other line
A milestone in how this cancer is treated.
Three-year event-free survival 86 percent with sintilimab added to chemoradiotherapy against 76 percent without (hazard ratio 0.
First FDA approval for nasopharyngeal carcinoma
Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines